Faron Pharmaceuticals Oy (FARN.L)

LSE • Market Data in GBP, Fundamentals in EUR Market GBP / Fundamentals EUR

£205.00

-£2.50

-1.20%

Last Update: 17 Jul 2025, 15:35

£229.51M

Market Cap

0.00

P/E Ratio (TTM)

P/E Ratio

—

Forward Dividend Yield

Forward Yield

£125.00 - £270.00

52 Week Range

FARN.L Stock Price Chart

Explore Faron Pharmaceuticals Oy interactive price chart. Choose custom timeframes to analyze FARN.L price movements and trends.

There is nothing to show.

FARN.L Company Profile

Discover essential business fundamentals and corporate details for Faron Pharmaceuticals Oy (FARN.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

17 Nov 2015

Employees

25.00

Website

https://www.faron.com

CEO

Juho Markku Jalkanen MSc,

Description

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

FARN.L Financial Timeline

Browse a chronological timeline of Faron Pharmaceuticals Oy corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 25 Feb 2026

Upcoming earnings on 27 Aug 2025

EPS estimate is -£0.06.

Earnings released on 27 Feb 2025

EPS came in at -£0.00 surpassing the estimated -£0.06 by +99.82%.

Earnings released on 27 Aug 2024

EPS came in at -£0.00 surpassing the estimated -£0.14 by +99.88%.

Stock split effective on 4 Jun 2024

Shares were split 151:125, changing the number of shares outstanding and the price per share accordingly.

Earnings released on 13 Mar 2024

EPS came in at -£0.00 surpassing the estimated -£0.14 by +99.87%, while revenue for the quarter reached £8.67K, beating expectations by +100.00%.

Earnings released on 29 Aug 2023

EPS came in at -£0.00 surpassing the estimated -£0.21 by +99.92%.

Earnings released on 2 Mar 2023

EPS came in at -£0.00 surpassing the estimated -£0.13 by +99.84%.

Earnings released on 30 Jun 2022

EPS came in at -£0.00 surpassing the estimated -£0.16 by +99.88%.

Earnings released on 31 Dec 2021

EPS came in at -£0.00 surpassing the estimated -£0.07 by +99.80%.

Earnings released on 30 Jun 2021

EPS came in at -£0.00 surpassing the estimated -£0.14 by +99.89%.

Earnings released on 31 Dec 2020

EPS came in at -£0.00 surpassing the estimated -£0.07 by +99.80%.

FARN.L Stock Performance

Access detailed FARN.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.